427 related articles for article (PubMed ID: 31698826)
1. When Does Alzheimer's Disease Really Start? The Role of Biomarkers.
Lloret A; Esteve D; Lloret MA; Cervera-Ferri A; Lopez B; Nepomuceno M; Monllor P
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698826
[TBL] [Abstract][Full Text] [Related]
2. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
[TBL] [Abstract][Full Text] [Related]
3. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
[TBL] [Abstract][Full Text] [Related]
4. Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.
Alexopoulos P; Roesler J; Thierjung N; Werle L; Buck D; Yakushev I; Gleixner L; Kagerbauer S; Ortner M; Grimmer T; Kübler H; Martin J; Laskaris N; Kurz A; Perneczky R
Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):587-97. PubMed ID: 26253588
[TBL] [Abstract][Full Text] [Related]
5. [New diagnostic guidelines for Alzheimer's disease by NIA/AA].
Ihara R
Nihon Rinsho; 2016 Mar; 74(3):386-94. PubMed ID: 27025074
[TBL] [Abstract][Full Text] [Related]
6. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
[TBL] [Abstract][Full Text] [Related]
7. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
Lista S; Dubois B; Hampel H
J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.
VanItallie TB
Metabolism; 2015 Mar; 64(3 Suppl 1):S51-7. PubMed ID: 25468143
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P
Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955
[TBL] [Abstract][Full Text] [Related]
10. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.
Berti V; Polito C; Lombardi G; Ferrari C; Sorbi S; Pupi A
Neurol Sci; 2016 May; 37(5):663-72. PubMed ID: 26792010
[TBL] [Abstract][Full Text] [Related]
11. [Toward Preclinical Trials for Alzheimer's Disease].
Miyagawa T; Iwatsubo T
Brain Nerve; 2017 Jul; 69(7):711-722. PubMed ID: 28739984
[TBL] [Abstract][Full Text] [Related]
12. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Jack CR; Albert MS; Knopman DS; McKhann GM; Sperling RA; Carrillo MC; Thies B; Phelps CH
Alzheimers Dement; 2011 May; 7(3):257-62. PubMed ID: 21514247
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective.
Lewczuk P; Mroczko B; Fagan A; Kornhuber J
Adv Med Sci; 2015 Mar; 60(1):76-82. PubMed ID: 25579841
[TBL] [Abstract][Full Text] [Related]
14. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Sperling RA; Aisen PS; Beckett LA; Bennett DA; Craft S; Fagan AM; Iwatsubo T; Jack CR; Kaye J; Montine TJ; Park DC; Reiman EM; Rowe CC; Siemers E; Stern Y; Yaffe K; Carrillo MC; Thies B; Morrison-Bogorad M; Wagster MV; Phelps CH
Alzheimers Dement; 2011 May; 7(3):280-92. PubMed ID: 21514248
[TBL] [Abstract][Full Text] [Related]
15. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease.
Shoji M
J Pharmacol Sci; 2012; 118(3):345-9. PubMed ID: 22382661
[TBL] [Abstract][Full Text] [Related]
16. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
17. The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades.
Molinuevo JL; Minguillon C; Rami L; Gispert JD
J Alzheimers Dis; 2018; 62(3):1067-1077. PubMed ID: 29562531
[TBL] [Abstract][Full Text] [Related]
18.
Leuzy A; Heurling K; Ashton NJ; Schöll M; Zimmer ER
Yale J Biol Med; 2018 Sep; 91(3):291-300. PubMed ID: 30258316
[TBL] [Abstract][Full Text] [Related]
19. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
Sakurai H; Hanyu H
Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
[TBL] [Abstract][Full Text] [Related]
20. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
